• 1
    Wanebo HJ, Falkson G, Order SE. Cancer of hepatobiliary system. In: DeVitaV, HellmanS, RosenbergSA, eds. Cancer: Principles and Practice of Oncology. Ed 3. Philadelphia: Lippincott, 1989: 836874.
  • 2
    Rustgi VK. Epidemiology of hepatocellular carcinoma. Ann Intern Med 1988; 108: 390391.
  • 3
    Bruix J, Calvet X, Bru C, Rodes J. Clinical pattern and natural history of hepatocellular carcinoma. Eur Clin Dig Dis 1992; 1: 97102.
  • 4
    Ford JM. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 1995; 9: 337361.
  • 5
    Gottesman MM, Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem 1988; 262: 1216312166.
  • 6
    Van Der Bliek AM, Borst P. Multidrug resistance. Adv Cancer Res 1989; 52: 165263.
  • 7
    Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137171.
  • 8
    Roninson IB. The role of MDR 1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992; 43: 95102.
  • 9
    Shen DW, Lu YG, Chin KW, Pastan I, Gottesman MM. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MDR 1 gene expression. J Cell Sci 1991; 98: 317322.
  • 10
    Park JG, Lee SK, Hong IG, Kim HS, Lim KH, Choe KJ, Kim WH, et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994; 86: 700705.
  • 11
    Leveille-Webster CR, Arias IM. The biology of P-glycoproteins. J Membr Biol 1995; 143: 89102.
  • 12
    Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of gp-170, the multidrug resistance gene product, in rat liver canalicular membrane vescicles. J Biol Chem 1989; 264: 1169311698.
  • 13
    Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385427.
  • 14
    Ford J, Hait WN. Pharmacology of drugs that alter multidrug resistance cancer. Pharmacol Rev 1990; 42: 155199.
  • 15
    Lai ECS, Choi FTK, Chen CH, Mok FPT, Fan ST, Tan ESY, Wong J. Doxorubicin for unresectable hepatocellular carcinoma: a prospective study on the addition of verapamil. Cancer 1990; 66: 16851687.
  • 16
    de Brauw LM, Van de Velde CJH, Tjaden UR, de Bruijn FA, Bell AVRJ, Hermans J, Zwaveling A. In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-flurorouracil concentration in tumor tissue. J Surg Res 1988; 44: 137145.
  • 17
    Burgener FA, Violante MR. Comparison of hepatic VX2 carcinoma after intra-arterial, intraportal and intraparenchymal tumor cell injection. An angiographic and computed tomographic study in the rabbit. Invest Radiol 1979; 14: 410414.
  • 18
    Chen MC, Tsang YM, Stark DD, Saini S, Brandhorst J, White DL, Engelstad B, et al. Hepatic metastases: rat model for imaging research. Magn Reson Imaging 1989; 7: 18.
  • 19
    Shouval D, Reid LM, Chakraborty PR, Ruiz-Opazo N, Morecki R, Gerber MA, Thung SN, et al. Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA. Cancer Res 1981; 41: 13421350.
  • 20
    Leveille-Webster CR, Arias IM. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin Cancer Res 1996; 2: 695703.
  • 21
    Shouval D, Schuger L, Levij IS, Reid L, Neeman Z, Shafritz DA. Comparative morphology and tumorigenicity of human hepatocellular carcinoma cell lines in athymic rats and mice. Virchow Archiv A Pathol Anat Histopathol 1988; 412: 595606.
  • 22
    Clarke E, Jenkins N, Nelson R, Ritchie H, Rise G, Singer JW. CT-2584, a novel anti-tumor agent, lacking apparent hematopoietic toxicity in vivo [Abstract]. Blood 1994; 84 (suppl): 52A.
  • 23
    Mazzanti R, Gatmitan Z, Croop JM, Shu H, Arias IM. Quantitative image analysis of rhodamine 123 transport by Adriamycin sensitive and resistant NIH 3T3 and human hepatocellular carcinoma (Alexander) cells. J Cell Pharmacol 1990; 1: 5056.
  • 24
    Miller JP, Overby LR. Australian antigen. In: RothfeldB, eds. Nuclear Medicine In Vitro. Philadelphia: Lippincott, 1974: 365383.
  • 25
    Woodwock DM, Jefferson S, Crowther PI Linsenmeyer, Chrojnowski GM, Williams B, Bertoncello I. Reversal of multidrug resistance pheno-type with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50: 41994203.
  • 26
    Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992; 17: 1821.
  • 27
    Zordan-Nudo T, Ling V, Liu Z, Georges E. Effect of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res 1993; 53: 59946000.
  • 28
    Ambudkar SV, Lelong IG, Zhang J, Cardarelli CO, Gottesman MM, Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulable ATP hydrolysis. Proc Natl Acad Sci U S A 1992; 89: 84728476.
  • 29
    Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JFR. An electron-microscope study of the mode of cell death induced by cancer chemo-therapeutic agents in population of proliferating normal and neoplastic cells. J Pathol 1975; 116: 129138.
  • 30
    Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 23532362.
  • 31
    Cotter TG, Glynn JM, Echeverri F, Green DR. The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cycle. Anticancer Res 1992; 12: 773780.
  • 32
    Kerr JFR, Winterford CM. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 20132026.